- Conditions
- Overweight and Obesity
- Interventions
- Apitegromab, Placebo, Tirzepatide
- Drug
- Lead sponsor
- Scholar Rock, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 7
- States / cities
- Chula Vista, California • Orlando, Florida • Chicago, Illinois + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Lack of Satiety
- Interventions
- placebo, digestion-resistant maltodextrin
- Other · Dietary Supplement
- Lead sponsor
- Iowa State University
- Other
- Eligibility
- 18 Years to 62 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Ames, Iowa
- Conditions
- Chronic Weight Management
- Interventions
- ASC35 Injection B, for subcutaneous use, ASC35 Placebo Injection B, for subcutaneous use, Tirzepatide
- Drug
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Elizabeth, New Jersey • Hamilton, New Jersey • Livingston, New Jersey + 4 more
- Conditions
- Diabetes Mellitus, Type 2, Obesity
- Interventions
- taVNS, Sham taVNS
- Device
- Lead sponsor
- Burrell College of Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Las Cruces, New Mexico
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Tirzepatide, Dulaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 13,299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Concord, California • Covina, California + 106 more
- Conditions
- Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Overweight or Obesity
- Interventions
- Olatorepatide, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Walnut Creek, California • Maitland, Florida • The Villages, Florida + 2 more
- Conditions
- Obesity
- Interventions
- Oral Azelaprag (BGE-105), Oral Placebo for Azelaprag (BGE-105), Tirzepatide, Tirzepatide Placebo
- Drug
- Lead sponsor
- BioAge Labs, Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 14
- States / cities
- Mesa, Arizona • Los Angeles, California • Montclair, California + 11 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Tirzepatide, Insulin Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,002 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 74
- States / cities
- Anaheim, California • Covina, California • Greenbrae, California + 68 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 28
- States / cities
- Huntington Park, California • Los Angeles, California • Montclair, California + 24 more
- Conditions
- Gastric Bypass Surgery, Obesity
- Interventions
- Liquid Meal, Solid Meal
- Other
- Lead sponsor
- St. Luke's-Roosevelt Hospital Center
- Other
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy, Healthy Volunteer, Healthy Volunteers, Healthy Adult, Healthy Male and Female Subjects, Healthy Subjects, Healthy Volunteers Only, Healthy Non-smokers
- Interventions
- Negative control, Avocado, Fat and fiber addition
- Other
- Lead sponsor
- University of Vermont Medical Center
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Type 2 Diabetes
- Interventions
- Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT)
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania
- Conditions
- COPD, Obesity & Overweight, Sarcopenia
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Post Bariatricsurgery, Hypoglycemia
- Interventions
- Exendin-(9-39), Atropine, GLP-1 and GIP
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2027
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Endometrial Cancer
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Diabetes, Gastric Bypass
- Interventions
- Mixed Meal Tolerance test, Hyperglycemic clamp
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Cystic Fibrosis, Pancreatic Insufficiency
- Interventions
- GLP-1, GIP
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Obesity
- Interventions
- Ribupatide, Semaglutide, Placebo
- Drug
- Lead sponsor
- Kailera
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 27
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 24 more
- Conditions
- The Effect of LCFA on Nutrient Absorption
- Interventions
- Benzocaine Infusion into Duodenum
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
- Interventions
- Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 10 more
- Conditions
- Pediatric Obesity, Meal Timing
- Interventions
- Meal-timing
- Other
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 13 Years to 19 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Obesity
- Interventions
- Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide
- Drug
- Lead sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Other
- Eligibility
- 35 Years to 60 Years
- Enrollment
- 30 participants
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- New Orleans, Louisiana